SCHEMBL16178801

SCHEMBL16178801

CC1CN(C(=O)NCc2ccc3c(c2)CCO3)CCN1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RYR2 Q92736 1/20 0.52
▸ RAB9A P51151 2/20 0.50
▸ NPC1 O15118 1/20 0.49
▸ POLB P06746 1/20 0.49
▸ FAAH O00519 1/20 0.45
▸ MAPT P10636 1/20 0.43
▸ EGLN1 Q9GZT9 1/20 0.43
▸ CHRM4 P08173 2/20 0.42
▸ EPHX2 P34913 2/20 0.42
▸ CHRM3 P20309 4/20 0.42
▸ TRPV1 Q8NER1 1/20 0.42
▸ CHEK1 O14757 2/20 0.41
▸ ADRB2 P07550 1/20 0.41
▸ CHRM2 P08172 1/20 0.41
▸ ADRB1 P08588 1/20 0.41
▸ CHRM5 P08912 1/20 0.41
▸ ADRA2A P08913 1/20 0.41
▸ CHRM1 P11229 1/20 0.41
▸ DRD2 P14416 1/20 0.41
▸ KCNE1 P15382 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16178753 0.84 CHRM3 (0.55) POLBCHRM3OPRK1SMN1; SMN2
SCHEMBL16178769 0.78 NPC1 (0.57) NPC1POLBSMN1; SMN2
SCHEMBL16178785 0.77 EPHX2 (0.62) RAB9APOLBMAPTEPHX2SMN1; SMN2
SCHEMBL13873843 0.76 EPHX2 (0.49) RYR2RAB9ANPC1POLBFAAH
SCHEMBL16178752 0.74 MLNR (0.48) EPHX2CHRM3CHRM2CHRM1
SCHEMBL14941502 0.74 EPHX2 (0.47) POLBMAPTEPHX2KCNH2SMN1; SMN2
SCHEMBL13873814 0.73 PRMT5 (0.46) RYR2RAB9ANPC1POLBFAAH
SCHEMBL20051405 0.73 RAB9A (0.66) RYR2RAB9ANPC1POLBFAAH
SCHEMBL3620383 0.73 RAB9A (0.70) RYR2RAB9ANPC1POLBFAAH
SCHEMBL4085189 0.71 RYR2 (0.46) RYR2RAB9ANPC1POLBFAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096614-B2 Therapeutically active thiazolo-pyrimidine derivatives UCB PHARMA SA (BE) 2015-08-04 — — US disclosed
US-20140315885-A1 Therapeutically Active Thiazolo-Pyrimidine Derivatives UCB PHARMA SA (BE) 2014-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315885-A1 Therapeutically Active Thiazolo-Pyrimidine Derivatives TPMT, IFNG, IRF3 RYR2 2839/4885RAB9A 1399/4885NPC1 1968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback